{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T18:09:05Z","timestamp":1771438145474,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 81874182"],"award-info":[{"award-number":["No. 81874182"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014717","name":"National Outstanding Youth Science Fund Project of National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. M-0334"],"award-info":[{"award-number":["No. M-0334"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenkang Three-year Clinical Research Foundation","award":["No. SHDC2020CR3031B"],"award-info":[{"award-number":["No. SHDC2020CR3031B"]}]},{"name":"Beijing Igandan Foundation","award":["GDXZ-08-02"],"award-info":[{"award-number":["GDXZ-08-02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04650-0","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:44:59Z","timestamp":1769168699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant tislelizumab, lenvatinib, and capecitabine for resected biliary tract cancer: a prospective phase II trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Yun","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An-Rong","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ti","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"4650_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Klumpen HJ, Malka D, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:127\u201340.","journal-title":"Ann Oncol"},{"key":"4650_CR2","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/s41416-020-0987-3","volume":"123","author":"JJG Marin","year":"2020","unstructured":"Marin JJG, Prete MG, Lamarca A, Tavolari S, Landa-Magdalena A, Brandi G, et al. Current and novel therapeutic opportunities for systemic therapy in biliary cancer. Br J Cancer. 2020;123:1047\u201359.","journal-title":"Br J Cancer"},{"key":"4650_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101936","volume":"84","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Edeline J, McNamara MG, Hubner RA, Nagino M, Bridgewater J, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat Rev. 2020;84:101936.","journal-title":"Cancer Treat Rev"},{"key":"4650_CR4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663\u201373.","journal-title":"Lancet Oncol"},{"key":"4650_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.18.02178","volume":"37","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37:1015\u201327.","journal-title":"J Clin Oncol"},{"key":"4650_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","volume":"401","author":"K Nakachi","year":"2023","unstructured":"Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023;401:195\u2013203.","journal-title":"Lancet"},{"key":"4650_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.critrevonc.2016.08.013","volume":"107","author":"DP Sohal","year":"2016","unstructured":"Sohal DP, Shrotriya S, Abazeed M, Cruise M, Khorana A. Molecular characteristics of biliary tract cancer. Crit Rev Oncol Hematol. 2016;107:111\u20138.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4650_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.894407","volume":"13","author":"L Xie","year":"2022","unstructured":"Xie L, Huang J, Wang L, Ren W, Tian H, Hu A, et al. Lenvatinib combined with a PD-1 inhibitor as effective therapy for advanced intrahepatic cholangiocarcinoma. Front Pharmacol. 2022;13:894407.","journal-title":"Front Pharmacol"},{"key":"4650_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1109292","volume":"14","author":"C Zhu","year":"2023","unstructured":"Zhu C, Xue J, Wang Y, Wang S, Zhang N, Wang Y, et al. Efficacy and safety of lenvatinib combined with PD-1\/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer. Front Immunol. 2023;14:1109292.","journal-title":"Front Immunol"},{"key":"4650_CR10","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3390\/curroncol30020132","volume":"30","author":"J Yang","year":"2023","unstructured":"Yang J, Jiang S, Chen Y, Zhang J, Deng Y. Adjuvant ICIs plus targeted therapies reduce HCC recurrence after hepatectomy in patients with high risk of recurrence. Curr Oncol. 2023;30:1708\u201319.","journal-title":"Curr Oncol"},{"key":"4650_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000437","author":"L Shen","year":"2020","unstructured":"Shen L, Guo J, Zhang Q, Pan H, Yuan Y, Bai Y, et al. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1\/2 study. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2019-000437.","journal-title":"J Immunother Cancer"},{"key":"4650_CR12","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1158\/1078-0432.CCR-19-3561","volume":"26","author":"J Xu","year":"2020","unstructured":"Xu J, Bai Y, Xu N, Li E, Wang B, Wang J, et al. Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric\/gastroesophageal junction adenocarcinoma. Clin Cancer Res. 2020;26:4542\u201350.","journal-title":"Clin Cancer Res"},{"key":"4650_CR13","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1634\/theoncologist.2019-0407","volume":"25","author":"Z Hao","year":"2020","unstructured":"Hao Z, Wang P. Lenvatinib in management of solid tumors. Oncologist. 2020;25:e302\u201310.","journal-title":"Oncologist"},{"key":"4650_CR14","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1111\/cas.13806","volume":"109","author":"T Kimura","year":"2018","unstructured":"Kimura T, Kato Y, Ozawa Y, Kodama K, Ito J, Ichikawa K, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018;109:3993\u20134002.","journal-title":"Cancer Sci"},{"key":"4650_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01317-7","volume":"8","author":"GM Shi","year":"2023","unstructured":"Shi GM, Huang XY, Wu D, Sun HC, Liang F, Ji Y, et al. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. Signal Transduct Target Ther. 2023;8:106.","journal-title":"Signal Transduct Target Ther"},{"key":"4650_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02437-2","volume":"18","author":"L Wang","year":"2020","unstructured":"Wang L, Zhu H, Zhao Y, Pan Q, Mao A, Zhu W, et al. Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience. J Transl Med. 2020;18:273.","journal-title":"J Transl Med"},{"key":"4650_CR17","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1097\/HEP.0000000000000760","volume":"82","author":"HC Wilbur","year":"2025","unstructured":"Wilbur HC, Soares HP, Azad NS. Neoadjuvant and adjuvant therapy for biliary tract cancer: advances and limitations. Hepatology. 2025;82:1287\u2013302.","journal-title":"Hepatology"},{"key":"4650_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231163785","volume":"15","author":"J Kefas","year":"2023","unstructured":"Kefas J, Bridgewater J, Vogel A, Stein A, Primrose J. Adjuvant therapy of biliary tract cancers. Ther Adv Med Oncol. 2023;15:17588359231163785.","journal-title":"Ther Adv Med Oncol"},{"key":"4650_CR19","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","volume":"33","author":"E Ben-Josef","year":"2015","unstructured":"Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33:2617\u201322.","journal-title":"J Clin Oncol"},{"key":"4650_CR20","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37:658\u201367.","journal-title":"J Clin Oncol"},{"key":"4650_CR21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9:694\u2013704.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4650_CR22","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853\u201365.","journal-title":"Lancet"},{"key":"4650_CR23","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1200\/JCO.21.02568","volume":"40","author":"J Bridgewater","year":"2022","unstructured":"Bridgewater J, Fletcher P, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study. J Clin Oncol. 2022;40:2048\u201357.","journal-title":"J Clin Oncol"},{"key":"4650_CR24","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1097\/JS9.0000000000002161","volume":"111","author":"Y Peng","year":"2025","unstructured":"Peng Y, Liang A, Chen Z, Yang B, Yu W, Deng J, et al. The efficacy of adjuvant chemotherapy for curative resected biliary tract cancers: a systematic review and network meta-analysis of randomized clinical trials. Int J Surg. 2025;111:2182\u201394.","journal-title":"Int J Surg"},{"key":"4650_CR25","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1245\/s10434-024-16799-0","volume":"32","author":"J Sharib","year":"2025","unstructured":"Sharib J, Rhodin KE, Liu A, McIntyre S, Bartholomew A, Masoud S, et al. Adjuvant cytotoxic chemotherapy may not be associated with a survival advantage for resected intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2025;32:2456\u201366.","journal-title":"Ann Surg Oncol"},{"key":"4650_CR26","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.7150\/thno.56539","volume":"11","author":"J Lin","year":"2021","unstructured":"Lin J, Cao Y, Yang X, Li G, Shi Y, Wang D, et al. Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics. 2021;11:4585\u201398.","journal-title":"Theranostics"},{"key":"4650_CR27","first-page":"4990","volume":"14","author":"L Guo","year":"2022","unstructured":"Guo L, Zhou F, Liu H, Kou X, Zhang H, Chen X, et al. Genomic mutation characteristics and prognosis of biliary tract cancer. Am J Transl Res. 2022;14:4990\u20135002.","journal-title":"Am J Transl Res"},{"key":"4650_CR28","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.7150\/ijms.48971","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhu X, Qiao X, Sun L, Tian Y, Yang Y, et al. FSIP2 can serve as a predictive biomarker for clear cell renal cell carcinoma prognosis. Int J Med Sci. 2020;17:2819\u201325.","journal-title":"Int J Med Sci"},{"key":"4650_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07365-4","volume":"20","author":"M Ueno","year":"2020","unstructured":"Ueno M, Ikeda M, Sasaki T, Nagashima F, Mizuno N, Shimizu S, et al. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. BMC Cancer. 2020;20:1105.","journal-title":"BMC Cancer"},{"key":"4650_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jtho.2022.09.217","volume":"18","author":"C Zhou","year":"2023","unstructured":"Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, et al. Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303): a phase 3, open-label, randomized controlled trial. J Thorac Oncol. 2023;18:93\u2013105.","journal-title":"J Thorac Oncol"},{"key":"4650_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000453","volume":"8","author":"J Desai","year":"2020","unstructured":"Desai J, Deva S, Lee JS, Lin CC, Yen CJ, Chao Y, et al. Phase ia\/ib study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. J Immunother Cancer. 2020;8:e000453.","journal-title":"J Immunother Cancer"},{"key":"4650_CR32","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12916-024-03356-5","volume":"22","author":"L Xu","year":"2024","unstructured":"Xu L, Chen J, Liu C, Song X, Zhang Y, Zhao H, et al. Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial. BMC Med. 2024;22:172.","journal-title":"BMC Med"},{"key":"4650_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.iliver.2023.08.003","volume":"2","author":"K Tan","year":"2023","unstructured":"Tan K, He X, Yuan H, Zhao S, Gong C, Zhao Y, et al. Evaluating tislelizumab, lenvatinib, and FOLFOX4-HAIC as a conversion therapy for unresectable hepatocellular carcinoma. ILIVER. 2023;2:163\u20139.","journal-title":"ILIVER"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04650-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04650-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04650-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:12:09Z","timestamp":1771434729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04650-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4650"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04650-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center (approval number: 2109243\u201321). All procedures conducted in this study adhered to the ethical standards of the institutional and\/or national research committee, Good Clinical Practice guidelines, as well as the Declaration of Helsinki and its subsequent amendments or equivalent ethical standards. Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided informed consent for the publication of any associated data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}